In the golden‑autumn season, the landmark grand event of the pharmaceutical industry in the Greater Bay Area kicks off as scheduled. From September 16 to 18, 2026, CPHI & PMEC China (Shenzhen) Exhibition was grandly held at Shenzhen Convention & Exhibition Center (Futian). Sichuan Xieli Pharma presented specialty APIs, natural extracts and customized CDMO solutions at Booth 9G20. Rooted in the Greater Bay Area and linking the Asia-Pacific pharmaceutical market, we gathered with partners from all sectors around the globe to jointly explore new opportunities for high quality development of the pharmaceutical industry.
Centering on core businesses of CDMO, APIs and natural extracts for this exhibition, Xieli Pharma built a professional blue and white themed booth and set up an open negotiation area, fully demonstrating the company’s profound accumulation of more than 40 year dedication to natural active ingredient extraction as well as R&D and production of specialty APIs. The company set up a professional team composed of international&domestic sales and technical backbones for on-site reception. Serving product technical consultation, regulatory Q&A and business docking for formulation enterprises, import and export traders, and nutraceutical manufacturers.
Spotlight On Star Products, Demonstrating Solid Strength In International Quality
A core product portfolio including Bile acid series, Citrus aurantium flavonoid series, Camptothecin series, Rutin/Troxerutin was showcased at the exhibition:
- Bile acid series (including ursodeoxycholic acid): Featuring mature and stable manufacturing processes, these products comply with pharmacopoeia standards of NMPA, FDA, EDQM, JP and other regions. Custom manufacturing and supporting quality research services are available, widely applied in hepatobiliary preparations and health-functional raw materials.
- Citrus aurantium flavonoid series (Diosmin, Hesperidin, Diosmin MPFF): Backed by full industrial chain control covering botanical raw material traceability, extraction & purification and quality testing, our products hold international registrations such as CEP and DMF. Serve as core raw materials for venous and vascular health preparations.
- Specialty varieties including Camptothecin, Rutin and Troxerutin: Supplied steadily to the global market for years. The company provides high-purity intermediates and APIs for downstream pharmaceutical companies, alongside flexible custom CDMO development services.
Founded in 1980, Sichuan Xieli Pharma is a National High-Tech Enterprise and one of China Top 100 Pharma Internationalization Enterprises. Three manufacturing sites are operated with certifications including FDA, EU GMP and Japan GMP. Its products are delivered to nearly 50 countries and regions worldwide, deeply integrated into the global pharmaceutical supply chain.
Leveraging the geographical advantages of the Greater Bay Area for CPHI Shenzhen, the exhibition attracted numerous purchasers from South China, Southeast Asia and overseas to visit Booth 9G20 for exchanges. Visitors mainly discussed topics including production capacity assurance, impurity control, international registration and custom development. In-depth on-site communications were carried out, and preliminary cooperation intentions were reached with many clients.
Global Expansion, Building a New Pharma Ecosystem
As a key gateway to the Asia-Pacific market, the Greater Bay Area serves as a strategic highland for pharmaceutical innovation and supply chain globalization. Through this CPHI Shenzhen exhibition, Xieli Pharma leverages the platform as a bridge to further deepen its presence in South China and expand its customer network across Southeast Asia and the broader Asia-Pacific region.
Looking ahead, Sichuan Xieli Pharm will remain committed to its mission of Working Together to Create a Health Business. With unwavering focus on compliant manufacturing and quality-first principles, the company will continue to innovate in natural extracts and specialty API technologies, enhance CDMO service capabilities, and partner with global stakeholders to build a stable and sustainable pharmaceutical raw material supply chain, supporting the international expansion of Chinese pharmaceutical ingredients.
